703 related articles for article (PubMed ID: 31088111)
41. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
42. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
Mitchell P; Holz FG; Hykin P; Midena E; Souied E; Allmeier H; Lambrou G; Schmelter T; Wolf S;
Retina; 2021 Sep; 41(9):1911-1920. PubMed ID: 33782365
[TBL] [Abstract][Full Text] [Related]
43. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
[TBL] [Abstract][Full Text] [Related]
44. Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Core JQ; Pistilli M; Daniel E; Grunwald JE; Toth CA; Jaffe GJ; Hua P; Martin DF; Ying GS; Maguire MG;
Ophthalmol Retina; 2021 Oct; 5(10):962-974. PubMed ID: 34126249
[TBL] [Abstract][Full Text] [Related]
45. THE INFLUENCE OF VITREOMACULAR ADHESION ON OUTCOMES AFTER AFLIBERCEPT THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
McKibbin MA; Suter CA; Willis TA
Retina; 2015 Oct; 35(10):1951-6. PubMed ID: 25932561
[TBL] [Abstract][Full Text] [Related]
46. Initial utilization of aflibercept in exudative age-related macular degeneration.
Cho H; Weber ML; Shah CP; Heier JS
Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
[TBL] [Abstract][Full Text] [Related]
47. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.
Veritti D; Sarao V; Parravano M; Arias L; Varano M; Lanzetta P
Eur J Ophthalmol; 2017 Jan; 27(1):74-79. PubMed ID: 27791249
[TBL] [Abstract][Full Text] [Related]
48. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
49. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
50. Subretinal pseudocyst: A novel optical coherence tomography finding in age-related macular degeneration.
Sacconi R; Mullins RF; Lutty GA; Borrelli E; Bandello F; Querques G
Eur J Ophthalmol; 2020 May; 30(3):NP24-NP26. PubMed ID: 31018677
[TBL] [Abstract][Full Text] [Related]
51. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
Arcinue CA; Ma F; Barteselli G; Sharpsten L; Gomez ML; Freeman WR
Am J Ophthalmol; 2015 Mar; 159(3):426-36.e2. PubMed ID: 25461263
[TBL] [Abstract][Full Text] [Related]
52. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
[TBL] [Abstract][Full Text] [Related]
53. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
54. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results.
Grewal DS; Gill MK; Sarezky D; Lyon AT; Mirza RG
Eye (Lond); 2014 Jul; 28(7):895-9. PubMed ID: 24833178
[TBL] [Abstract][Full Text] [Related]
55. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
[TBL] [Abstract][Full Text] [Related]
56. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.
Chang AA; Li H; Broadhead GK; Hong T; Schlub TE; Wijeyakumar W; Zhu M
Ophthalmology; 2014 Jan; 121(1):188-192. PubMed ID: 24144450
[TBL] [Abstract][Full Text] [Related]
57. Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration.
Abdolrahimzadeh S; Gharbiya M; Formisano M; Bertini F; Cerini A; Pacella E
Curr Eye Res; 2019 Sep; 44(9):1000-1005. PubMed ID: 30999772
[No Abstract] [Full Text] [Related]
58. Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration.
Dans KC; Freeman SR; Lin T; Meshi A; Olivas S; Cheng L; Amador-Patarroyo MJ; Freeman WR
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):741-748. PubMed ID: 30806775
[TBL] [Abstract][Full Text] [Related]
59. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
60. Intravitreal Aflibercept for Neovascular AMD: Short-Term Clinical Effects of Intravitreal Aflibercept Injection as a Predictor of Long-Term Results.
Liu EM; Shah G; Blinder KJ; Smith BT; Thomas MA
Ophthalmic Surg Lasers Imaging Retina; 2015; 46(10):1021-7. PubMed ID: 26599244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
